JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study (NCT06882876) | Clinical Trial Compass
By InvitationPhase 1
JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study
China20 participantsStarted 2025-07-10
Plain-language summary
This is an open-label, single-center, single-arm phase Ib clinical trial. The aim of this study is to assess the safety and efficacy of JS014 in combination with Toripalimab and transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC). The primary endpoint is the safety and tolerability, while the secondary endpoints include objective response rate (ORR), disease control rate (DCR), time to progression (TPP), progression-free survival (PFS), and overall survival (OS).
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Sign the informed consent form, voluntarily participate in this study, good compliance and follow-up cooperation.
* Histologically or pathologically confirmed unresectable hepatocellular carcinoma;
* Male or female patients aged 18-75 years;
* Eastern Cooperative Oncology Group (ECOG) PS score of 0-1;
* Child-Pugh score of ≤7;
* BCLC/B stage; not previously treated with anti-cancer therapy; at least one measurable lesion (according to RECIST 1.1 criteria).
* Sufficient organ function in vital organs (excluding serious functional impairment in the heart, lung, liver, kidney, bone marrow, nervous system, and endocrine systems).
Exclusion Criteria:
* Diagnosed with fibrolamellar carci-noma of liver, intrahepatic cholangiocarcinoma, and mixed carcinoma;
* Within 28 days prior to the start of the study, the participant received treatment with another investigational drug or participated in another clinical study for a different therapeutic indication.;
* Based on the investigator's judgment, the patient is expected to live for less than 12 weeks;
* Uncontrolled pleural effusion, pericardial effusion, or ascites of moderate volume or more;
* Current or past history of central nervous system metastasis;
* Have a history of psychotropic drug abuse or drug use;
* Hereditary or acquired tendency towards bleeding and thrombosis, a thromboembolic event occurred within the past 6 months;
* Have a history of severe allergy to any monoclonal antibody, Toripalimab , …
What they're measuring
1
The rate of adverse events
Timeframe: Two years
Trial details
NCT IDNCT06882876
SponsorXiangya Hospital of Central South University